WebNews

Please enter a web search for web results.

NewsWeb

Hospital News
hospitalnews. com > people-living-with-parkinsons-face-long-wait-times-inconsistent-care-across-canada

People living with Parkinson's face long wait times, inconsistent care across Canada

2+ day, 16+ hour ago  (336+ words) Accessing Parkinson's care in Canada can be inconsistent and often depends on geography, income, and available services, leaving many in the Parkinson's community waiting years for a diagnosis or without access to a specialist. Throughout April, Parkinson Canada is working…...

Knowridge Science Report
knowridge. com > 2026 > 04 > hidden-eye-disease-may-signal-future-alzheimers-disease

Hidden eye disease may signal future Alzheimer's disease

3+ hour, 11+ min ago  (852+ words) Glaucoma is often called the "silent thief of sight" because it can slowly damage vision without clear warning signs. Many people do not notice anything is wrong until their eyesight has already been affected. This disease harms the optic nerve,…...

@WABI_TV5
wabi. tv > 04/08/2026 > parkinsons-awareness-month-highlights-need-early-therapy-experts-say

Parkinson's Awareness Month highlights need for early therapy, experts say

4+ day, 13+ hour ago  (217+ words) ELLSWORTH, Maine (WABI) -According to the Parkinson's Foundation, nearly 90, 000 people are newly diagnosed annually with the progressive brain disorder. Experts say depending on the person, symptoms can generally develop slowly over years. These include tremors, slowness of movement, limb stiffness,…...

healiotwo
healio. com > news > rheumatology > 20/26/0410 > data-hydralazine-does-not-increase-vasculitis-risk-in-cardiovascular-disease

Data: Hydralazine does not increase vasculitis risk in cardiovascular disease

3+ hour, 58+ min ago  (199+ words) Hydralazine does not increase the risk for vasculitis in individuals using the medication for cardiovascular disease, according to findings published in JAMA Network Open. The overall study population included 583, 136 adults from Ontario, Canada, with a mean age of 73 years (standard…...

Daily Sabah
dailysabah. com > life > health > experts-urge-early-treatment-to-slow-parkinsons-progression

Experts urge early treatment to slow Parkinson's progression

6+ hour, 10+ min ago  (609+ words) Combining medication with physical therapy in the early stages of Parkinson's disease can significantly slow its progression, according to medical experts. Dr. G'zde "nal, a neurologist at Istanbul's Kanuni Sultan S'leyman Training and Research Hospital, said Parkinson's is a progressive…...

BIOENGINEER. ORG
bioengineer. org > correcting-genetic-links-tmem175-scarb2-ctsb-in-parkinsons

Correcting Genetic Links: TMEM175, SCARB2, CTSB in Parkinson's

4+ hour, 48+ min ago  (830+ words) In an era marked by relentless advancements in neurogenetics, recent developments have shed new light on the intricate genetic architecture underlying Parkinson's disease (PD). The latest author correction published by Sun, Schulte, Gasser, and colleagues in npj Parkinson's Disease delves…...

taiwannews. com. tw
taiwannews. com. tw > en > news > 6339186

Roche receives CE mark for new Elecsys Nf L blood test to detect neuroinflammation in multiple sclerosis | Taiwan News | Apr. 13, 2026 13: 00

15+ hour, 28+ min ago  (282+ words) About Elecsys" Nf LRoche's Elecsys Nf L is an in vitro quantitative immunoassay for the measurement of Nf L protein in human serum and plasma. Elecsys Nf L is intended to be used to reflect neuroinflammation in adult subjects diagnosed…...

Yahoo Finance
finance. yahoo. com > sectors > healthcare > articles > roche-receives-ce-mark-elecsys-050000685. html

Roche receives CE mark for new Elecsys Nf L blood test to detect neuroinflammation in multiple sclerosis

1+ hour, 36+ min ago  (275+ words) This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods. By providing deeper insight into underlying neuroinflammatory activity, Elecsys Nf L has the potential to enable effective MS monitoring and…...

@PRNewswire
prnewswire. com > news-releases > galmed-announces-the-breakthrough-development-of-a-brain-penetrating-new-formulation-of-its-scd1-inhibitor-aramchol-302738096. html

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol

4+ day, 1+ hour ago  (640+ words) 98% of drugs do not reach the brain, as the blood'brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has. .. - 98% of drugs do not reach the brain, as the blood'brain barrier (BBB) separates peripheral blood circulation…...

The Manila Times
manilatimes. net > 04/09/2026 > tmt-newswire > pr-newswire > oncoc4-announces-first-participants-dosing-in-phase-12-clinical-trial-of-onc-841-for-the-treatment-of-alzheimers-disease > 2317146

Onco C4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease

4+ day, 2+ hour ago  (252+ words) The Manila Times Onco C4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease ONC-841 is the world's first and only clinical stage anti-SIGLEC 10 antibody. The drug was initially developed, and is in a…...